Heron Therapeutics, Inc. Share Price Today: Live Updates & Key Insights
Heron Therapeutics, Inc. share price today is $0.7963, up -4.74%. The stock opened at $0.815 against the previous close of $0.8173, with an intraday high of $0.8241 and low of $0.765.
Heron Therapeutics, Inc. Share Price Chart
Heron Therapeutics, Inc.
Heron Therapeutics, Inc. Share Price Performance
Heron Therapeutics, Inc. Institutional Holdings
Heron Therapeutics, Inc. Market Status
Heron Therapeutics, Inc. Fundamentals
Market Cap 146.80 M
PB Ratio 11.0513
PE Ratio 0.0
Enterprise Value 241.85 M
Total Assets 255.88 M
Volume 2039536
Heron Therapeutics, Inc. Company Financials
About Heron Therapeutics, Inc. & investment objective
Company Information Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
Organisation Biotechnology
Employees 128
Industry Biotechnology
CEO Mr. Craig Alexander Collard
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
Heron Therapeutics, Inc. FAQs
What is the share price of Heron Therapeutics, Inc. today?
The current share price of Heron Therapeutics, Inc. is $0.7963.
Can I buy Heron Therapeutics, Inc. shares in India?
Yes, Indian investors can buy Heron Therapeutics, Inc. shares by opening an international trading and demat account with Motilal Oswal.
How to buy Heron Therapeutics, Inc. shares in India?
You can easily invest in Heron Therapeutics, Inc. shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Heron Therapeutics, Inc. shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Heron Therapeutics, Inc..
Can I buy fractional shares of Heron Therapeutics, Inc.?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of Heron Therapeutics, Inc.?
Heron Therapeutics, Inc. has a market cap of $146.80 M.
In which sector does Heron Therapeutics, Inc. belong?
Heron Therapeutics, Inc. operates in the Biotechnology sector.
What documents are required to invest in Heron Therapeutics, Inc. stocks?
To invest, you typically need:
What is the PE and PB ratio of Heron Therapeutics, Inc.?
The PE ratio of Heron Therapeutics, Inc. is N/A and the PB ratio is 11.05.